{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:30:28Z","timestamp":1787031028067,"version":"build-2736575974"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cent Nerv Syst Dis"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:p>Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of partial-onset seizures. Structurally, it belongs to the dibenzazepine family and is closely related to carbamazepine and oxcarbazepine. Its main mechanism of action is by blocking the voltage-gated sodium channel. ESL is a pro-drug that is rapidly metabolized almost exclusively into S-licarbazepine, the biologically active drug. It has a favorable pharmacokinetic and drug-drug interaction profile. However, it may induce the metabolism of oral contraceptives and should be used with caution in females of child-bearing age. In the pre-marketing placebo-controlled clinical trials ESL has proven effective as adjunctive therapy in adult patients with refractory of partial-onset seizures. Best results were observed on a single daily dose between 800 and 1200 mg. In general, ESL was well tolerated, with most common dose-related side effects including dizziness, somnolence, headache, nausea and vomiting. Hyponatremia has been observed (0.6%-1.3%), but the incidence appears to be lower than with the use of oxcarbazepine. There is very limited information on the use of ESL in children or as monotherapy.<\/jats:p>","DOI":"10.4137\/jcnsd.s4888","type":"journal-article","created":{"date-parts":[[2011,7,20]],"date-time":"2011-07-20T17:02:31Z","timestamp":1311181351000},"page":"JCNSD.S4888","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy"],"prefix":"10.4137","volume":"3","author":[{"given":"Rajinder P.","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Neurology, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge J.","family":"Asconap\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,7,20]]},"reference":[{"key":"bibr1-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0442"},{"key":"bibr2-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"bibr3-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7511.2009.01337.x"},{"key":"bibr4-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1021\/jm980627g"},{"key":"bibr5-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00984.x"},{"key":"bibr6-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00231-5"},{"key":"bibr7-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.01.014"},{"key":"bibr8-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.43600.x"},{"key":"bibr9-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(01)00584-6"},{"key":"bibr10-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.10.005"},{"key":"bibr11-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2007.08.006"},{"key":"bibr12-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.07.010"},{"key":"bibr13-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.14104.x"},{"key":"bibr14-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005279364"},{"key":"bibr15-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200506050-00001"},{"key":"bibr16-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200506040-00002"},{"key":"bibr17-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.549"},{"key":"bibr18-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200304050-00001"},{"key":"bibr19-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0414-1"},{"key":"bibr20-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46119"},{"key":"bibr21-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01233.x"},{"key":"bibr22-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003740861"},{"key":"bibr23-JCNSD.S4888","volume-title":"European Medicines Agency. CHMP Assessment Report for Exalief: International Nonproprietary name: ESL acetate","year":"2009"},{"key":"bibr24-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47255"},{"key":"bibr25-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00691.x"},{"key":"bibr26-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.01.014"},{"key":"bibr27-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01946.x"},{"key":"bibr28-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01218.x"},{"key":"bibr29-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008319706"},{"key":"bibr30-JCNSD.S4888","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60460-7"}],"container-title":["Journal of Central Nervous System Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/JCNSD.S4888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.4137\/JCNSD.S4888","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/JCNSD.S4888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:00:02Z","timestamp":1777392002000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.4137\/JCNSD.S4888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":30,"alternative-id":["10.4137\/JCNSD.S4888"],"URL":"https:\/\/doi.org\/10.4137\/jcnsd.s4888","relation":{},"ISSN":["1179-5735","1179-5735"],"issn-type":[{"value":"1179-5735","type":"print"},{"value":"1179-5735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}